Bookmark and Share

Last Minute:          For more news, click here.

Authentication
       
       
Remember me? 

Fall of
--0.39 (+0.99%) Gilead Sciences - [Ticker: GILD]Chart Gilead Sciences  News Gilead Sciences  Download Historical Prices for Metastock Gilead Sciences and Others  Technical Analysis Gilead Sciences  
Last Trade71.55Last Trade Time2018-12-03 - 00:00:00
Variation--0.39 (+0.99%)Open72.74
High72.90Low71.52
Volume2,159,096Average Volume (3m)0
YieldBid / Ask74.80 x 800 - 74.82 x 1,000
Former Close71.9452 Week Range[0.00 - 0.00]
PER0.00%EPS0.00
Ex-Dividend DateDividend Payment
Market Capitalization0 1 Year Price-Target0.00
Note: The data may have some minutes of delay.
Watch more quotes

Intraday   5 days   1 month   3 months   6 months   1 year   2 years   5 years   10 years            Use this chart on your website!
Gilead Sciences -  [Ticker: GILD] chart
Change to Gilead Sciences Interactive Technical Analysis Chart

Last 10 Forum Topics about Gilead Sciences:
No topics about Gilead Sciences [GILD] have been found, but a search on the Forum for more topics related to Gilead Sciences is advised.

 News about Gilead Sciences [GILD]:   (ordered by relevance)
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients  Business Wire Gilead Sciences (NASDAQ:GILD) Has A Rock Solid Balance Sheet  Nasdaq Gilead Sciences Irish pharma unit records $1.84bn loss  The Irish Times Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS  Business Wire CSRWire - Gilead Sciences Expresses Thanks for the Researchers, Scientists and Frontline Healthcare Workers  CSRwire.com Gilead Sciences to Present at Upcoming Investor Conference  Business Wire Gilead Sciences, Inc: An Undervalued Acquisition Machine?  Sick Economics Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint  Yahoo Finance Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy  Yahoo Finance Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline  Business Wire Gilead Sciences Awards Over $1.5 Million USD In Grants Supporting Communities To Help End The HIV Epidemic In Asia Pacific  ACROFAN USA Gilead Sciences' Trodelvy marketing application OK'd in Europe for breast cancer  Seeking Alpha 'Inside the Innovation:' Oncology Leaders Discuss Life at  CSRwire.com Gilead Says Co's Bold Ambition Of Transforming Triple-Negative Breast Cancer Treatment To Be Highlighted With New Data At SABCS  Benzinga Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus  Entrepreneur Gilead Sciences Inc. Partners with Center for Translational Antiviral Research to Test Oral Remdesivir Variant  Georgia State University News Gilead Is A Solidly Profitable, High Dividend-Yielding Stock  Seeking Alpha Elton John AIDS Foundation and Gilead Sciences' new campaign highlights voices of those with HIV  Gay Times Magazine NRx Soars as Drug Benefits Remdesivir-Treated Covid Patients  Bloomberg Merck and Gilead Pause HIV Study out of "Abundance of Caution"  BioSpace Opinion: Why corporate philanthropy must stand against stigma  Devex Gilead to pay $745m for three oncology programmes from Arcus Biosciences  PMLiVE Gilead eyes outpatient approval for $7 billion Covid drug remdesivir - San Francisco Business Times  San Francisco Business Times AIDS Prevention Drug TRUVADA Found Obvious by Taiwan Intellectual Property Court (Gilead Sciences, Inc. v Yikang Pharmaceutical Co., Ltd.)  Lexology Breakeven On The Horizon For Integral Ad Science Holding Corp. (NASDAQ:IAS)  Nasdaq Gilead Sciences, Merck collaborate to evaluate Trodelvy in combo with Keytruda  Medical Dialogues John Watters Is The President & COO of Mandiant, Inc. (NASDAQ:MNDT) And They Just Picked Up 7.0% More Shares  Nasdaq Should You Be Adding Guaranty Federal Bancshares (NASDAQ:GFED) To Your Watchlist Today?  Nasdaq 3 Dividend Stocks That Are Dirt Cheap Right Now  Motley Fool Future Outlook on Leishmaniasis Treatment Market by Forecast to 2021 to 2028 with In-depth Analysis of Leading Players ? Sanofi SA, Sequus Pharmaceuticals Inc., Paladin Labs Inc  Medgadget Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021  Business Wire Gilead Sciences wins reversal of $1.2 bln award in patent case with Bristol Myers  Reuters At CAGR 19.7%, CAR-T Cell Therapy Market Size to hit USD  GlobeNewswire GSK aims at NASH target with $1bn-plus Arrowhead alliance -  pharmaphorum Gilead Sciences Announces Second Quarter 2021 Financial Results  Business Wire The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained ...  KULR-TV Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet  Motley Fool Cystic Fibrosis Drug Market Global Analysis, Segments, Size, Share, Industry Growth & Recent Trends by  EIN News G1 Therapeutics Announces Init  GuruFocus.com Gilead: 'Cell therapy at early stages of penetration' - BioProcess Insider  BioProcess Insider European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options  gilead.com Gilead Sciences Announces VekluryŽ Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia  Business Wire 1 Cancer Stock on Buyout Watch in 2022  Motley Fool Gilead Sciences Might Return To The Glory Days Of Past  Seeking Alpha Gilead Sciences.....a Titan Reborn? | Healthcare Stocks  Sick Economics Gilead Sciences Q3 CAR T-Cell Therapy Sales Increase 51 Percent  Precision Oncology News Gilead shares positive findings for COVID-19 treatment  OutSourcing-Pharma.com Gilead's slumping COVID-19 drug takes another hit with study showing no real benefit  FiercePharma After Biden admin failed to submit FDA chief paperwork on time, hopes for a speedy confirmation vote likely dashed: report  FiercePharma Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India  Business Wire Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program  Business Wire Gilead says aware of counterfeit HIV medicines being distributed in U.S.  Reuters Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021  Business Wire Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021  Business Wire Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q3 2021 Results - Earnings Call Transcript  Seeking Alpha Gilead Sciences: At An Inflection Point (Once Again)  Seeking Alpha Here's the Key to Gilead Sciences' Q4 Earnings Beat  Motley Fool Could Moderna Take Down Gilead Sciences?  Motley Fool Gilead Sciences Seeks Approval for Twice-Annual HIV-1 Medication  BioSpace CSRWire - Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity  CSRwire.com Why Gilead Sciences Stock Jumped Today  Motley Fool Gilead Sciences considered Durham before picking Raleigh for 275-job expansion - Triangle Business Journal  Triangle Business Journal Gilead to require U.S. workers receive COVID-19 vaccine  Reuters Gilead's Veklury shows 'no antiviral effects,' small WHO study says as company stands by COVID med  FiercePharma BioNTech to buy T-cell receptor facility and platform from Gilead Sciences  MarketWatch Stocks making the biggest moves after the bell: Amazon, Twitter, Gilead Sciences & more  CNBC Gilead Sciences Completes Acquisition of MYR GmbH  Business Wire Controversial rapper DaBaby postpones multiple shows, including Milwaukee  Milwaukee Journal Sentinel Gilead, Merck begin phase 2 study of weekly two-drug HIV regimen  Healio Could mRNA make us superhuman?  BBC News Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research  Business Wire India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports  FiercePharma Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV  Yahoo Finance Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021  Business Wire Where Will Gilead Sciences Be in 1 Year?  Motley Fool Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research  Business Wire Gilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds  FiercePharma A Look Into Gilead Sciences Price Over Earnings  Yahoo Finance What Is The Ownership Structure Like For Gilead Sciences, Inc. (NASDAQ:GILD)?  Simply Wall St Gilead CEO Got $19 Million Pay in Blockbuster Year for Company  BioSpace Gilead to Pay Investors $1.8 Million in Fees Over Truvada Files  Bloomberg Law Gilead Sciences Announces Updated 2020 Guidance  Business Wire Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021  Business Wire I went back into the closet at work ? until I became pregnant  PinkNews Arcus' CMO Grossman jumps ship to join Gilead's cancer push -  pharmaphorum WHO calls for lower prices on Gilead drug for Covid-linked black fungus  Financial Times Gilead's Kite enters leukemia with Tecartus FDA approval, overlapping Novartis' CAR-T rival Kymriah  FiercePharma Rand Paul reveals his wife invested in remdesivir parent company early last year  MarketWatch Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion  Nasdaq Is Gilead Sciences, Inc. (GILD) Stock Over or Undervalued?  InvestorsObserver Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 1.4% Return On Equity?  Simply Wall St Best Legal Departments: Gilead Sciences Navigates Development of COVID-19 Treatment Amid Legal Ops Revamp | Corporate Counsel  Law.com After Gilead Sciences' Year Of Acquisitions, 2021 Is When It Becomes An Oncology Powerhouse  Seeking Alpha Gilead nixes Veklury COVID-19 trial as vaccines roll out, more convenient drugs emerge for outpatients  FiercePharma Gilead Sciences considered Atlanta before selecting Raleigh for 275-job expansion - Atlanta Business Chronicle  Atlanta Business Chronicle Gilead Expands in NC Amidst Profitable Second Quarter  BioSpace Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes  FiercePharma Gilead guts its filgotinib plans, dealing a blow to O'Day's diversification dream  FiercePharma Gilead's Kite matches Bristol Myers with Yescarta CAR-T win in earlier lymphoma  FiercePharma Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients  Entrepreneur
For more news about Gilead Sciences click here:
Gilead Sciences News
Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2021 - TR4DER.com, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources